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Abstract
Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and
chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint
inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal
antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However,
the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified
research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-
blockade immunotherapy and current issues in its clinical use.
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Background
Cancer immunotherapy, although controversial for many
years, reached a turning point in 2014. Antibodies that
specifically block PD-1 were approved for melanoma in
2014 and for non-small-cell lung cancer (NSCLC) in
2015 in the United States, European Union, and Japan.
The success of clinical trials with novel drugs targeting
immune-checkpoint molecules such as PD-1 led to a
paradigm shift in cancer treatment. Since a PD-1 block-
ade targets lymphocytes rather than cancer cells, it has a
long-term therapeutic effect that persists even when
cancers cause mutations. Furthermore, the PD-1 block-
ade is effective against many types of tumors because it
enhances the anti-tumor activity of cytotoxic T lympho-
cytes (CTLs), which recognize various tumor-specific
antigens. Several companies are currently conducting
phase 3 trials for different tumor types, including renal-
cell cancer (RCC), bladder cancer, head and neck cancer,
ovarian cancer, and brain cancer. Although PD-1 block-
ade has dramatically improved the response rate for sev-
eral cancers, three questions remain to be answered: 1)
Why do some patients not respond to PD-1 blockade?
2) What is the best combination therapy using PD-1
blockade? 3) What predictive biomarkers can be used to
distinguish responsive and unresponsive patients? Here
we review the development of immunotherapy targeting
the PD-1/PD-L1 signaling pathway and discuss the is-
sues that still need to be resolved in clinical studies.
History of cancer immunotherapy
The concept of cancer immunotherapy goes back to the
late nineteenth century. In 1891, a young New York sur-
geon named William Coley began intra-tumoral injec-
tions of bacterial products and observed tumor
shrinkage in patients with sarcoma [1]. Almost a century
later, the role of dendritic cells and their receptors in
sensing microorganisms in the innate immune system
was discovered [2, 3]. The molecular identification of
cancer antigens created new approaches for effective im-
munotherapies [4]. In addition, the importance of IFN-γ
and adaptive immunity in cancer immunosurveillance
was demonstrated in preclinical tumor models using
IFN-γR−/− and RAG2−/− mice [5]. These findings stimu-
lated research into strategies to induce anti-tumor re-
sponses and led to immunotherapies such as cytokine
therapy, peptide vaccine, dendritic-cell vaccine, and
adoptive T-cell therapy. Most of these therapies were un-
successful, and one primary reason was a lack of under-
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Immune checkpoints
T-cell activating (accelerator) and inhibitory (brake) re-
ceptors regulate the balance between immune response
and immune tolerance. The activation of naïve T cells
requires both antigen presentation (signal 1) and a sec-
ond signal sent through costimulatory receptors such as
CD28 (signal 2) (Fig. 1) [7]. When ligated by B7 mole-
cules such as CD80 (B7-1) or CD86 (B7-2), CD28 core-
ceptors on T cells deliver a positive costimulatory signal,
whereas CTLA-4 coreceptors deliver a negative co-
inhibitory signal. PD-1, like CTLA-4, belongs to the
CD28 family and delivers a negative signal when it inter-
acts with its ligands, PD-L1 (B7-H1 or CD274) and PD-
L2 (B7-DC or CD273), which belong to the B7 family
(Fig. 1) [8–10].
T cells have immune checkpoints such as PD-1 and
CTLA-4 to reduce autoimmune responses against self-
tissues by overly exuberant immune responses to infec-
tion. While most cancer immunotherapies accelerate T-
cell activity, immune-checkpoint inhibitors release the
immune system’s brakes to unleash anti-tumor immune
responses.
Immunoinhibitory mechanism by PD-1
PD-1 was discovered in 1992 (Fig. 2). Ishida et al. iso-
lated the gene that encodes PD-1 by cDNA subtraction
in apoptosis-induced murine T-cell lines. PD-1 is mainly
expressed on activated CD4+ T cells and CD8+ T cells as
well as on B cells in the periphery [11–13]. The
activation-induced expression of PD-1 suggests that PD-
1 regulates late-phase immune responses (effector phase,
memory response, chronic infection, etc.) in the periph-
eral tissues, rather than the early induction phase in the
lymphoid organs.
PD-1’s extracellular region consists of a single IgV-like
domain, and its cytoplasmic region contains an
immunoreceptor tyrosine-based inhibitory motif (ITIM)
and an immunoreceptor tyrosine-based switch motif
(ITSM). Upon ligation with its physiological ligand (PD-
L1 or PD-L2), PD-1 suppresses T-cell activation by
recruiting SHP-2, which dephosphorylates and inacti-
vates Zap 70, a major integrator of T-cell receptor
(TCR)-mediated signaling [14, 15]. As a result, PD-1 in-
hibits the T-cell proliferation and effector functions such
as IFN-γ production and cytotoxic activity.
The promoter region of the Pdcd1 gene has two
transcription-factor binding sites that are critical in
regulating PD-1 expression. In naïve T cells, TCR-
mediated calcium influx initiates Pdcd1 transcription by
activating NFATc1, which binds to the 5′-promoter re-
gion of the Pdcd1 gene (at position −1160 relative to the
transcription start site) [16]. On the other hand, in
chronically activated (“exhausted”) T cells, interferon-α
(IFN-α) causes prolonged Pdcd1 transcription by the
binding of the transcription factor IRF9 to the Pdcd1
promoter (at position −1040 relative to the transcription
start site) [17]. In addition, the Pdcd1 promoter region
(located 500–1500 base pairs upstream of the initiation
codon) is demethylated during chronic infection, causing
high PD-1 expression in exhausted CD8+ T cells [18].
While exhausted CD8+ T cells express high eomesoder-
min (EOMES), which is regulated by transcription factor
FoxO1, FoxO1 also binds the Pdcd1 promoter and en-
hances PD-1 expression [19].
PD-1 deficiency and autoimmunity
PD-1’s immunoinhibitory function was elucidated by
characterizing the autoimmune phenotype of PD-1–defi-
cient mice, in which PD-1 deficiency leads to a loss of
peripheral tolerance and the subsequent development of
autoimmunity (Fig. 2) [20, 21]. PD-1–deficient mice de-
velop different autoimmune diseases depending on their


















Fig. 1 Costimulatory molecules that positively or negatively regulate immune responses
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genetic background: C57BL/6-Pdcd1−/− mice develop
lupus-like arthritis and glomerulonephritis with IgG3
and C3 deposits [20]. BALB/c-Pdcd1−/− mice develop
fetal dilated cardiomyopathy with a concomitant produc-
tion of autoantibodies against cardiac troponin I [21,
22]. NOD-Pdcd1−/− mice develop type I diabetes with
extensive destruction of the islets [23]. Furthermore,
PD-1–deficient mice crossed with H-2Ld–specific 2C-
TCR transgenic mice on the H-2b/d background develop
a chronic and systemic graft-versus-host-like disease
[20]. These findings indicate that PD-1 negatively regu-
lates immune responses and is essential for maintaining
peripheral tolerance.
Distinct physiological functions of PD-1 and CTLA-4
Although PD-1 and CTLA-4 are both induced on acti-
vated T cells, they are expressed at different stages of the
immune response. CTLA-4 is closely related to CD28,
but binds CD80 and CD86 with a much higher affinity
than does CD28 [24]. CTLA-4 is constitutively expressed
on regulatory T (Treg) cells, and transiently expressed
on activated T cells at the early induction phase after
antigen stimulation [25]. In contrast, PD-1 is expressed
on activated T cells at the late effector phase, and high
and persistent PD-1 expression has been observed on
exhausted CD8+ T cells during chronic viral infection
[26, 27]. CTLA-4 is continuously internalized by
interactions with the adaptor complex AP2 and is almost
undetectable on the cell surface during T-cell activation;
in contrast, PD-1 lacks an AP2-binding motif, which
may allow its sustained expression on the surface of acti-
vated T cells [28].
Although both PD-1 and CTLA-4 are immune
checkpoints, they regulate different phases of the im-
mune response. CTLA-4 blocks early T-cell activation
in the lymphoid organs, whereas PD-1 inhibits ef-
fector T-cell activity at later-stage immune responses
in peripheral tissues and in the tumor microenviron-
ment. PD-1 and CTLA-4 also have distinct inhibitory
mechanisms. CTLA-4 completely blocks costimulation
by CD28 through its stronger affinity for B7 mole-
cules, whereas PD-1’s inhibitory function depends
mostly on its recruitment of SHP-2 [29–32]. These
differences in expression and inhibitory mechanisms
are probably responsible for the different autoimmune
phenotypes of PD-1 and CTLA-4 deficiency. CTLA-4-
deficient mice develop devastating autoimmune dis-
eases and massive and systemic lymphoproliferation,
and die within 5 weeks of birth [33]. In contrast, PD-
1–deficient mice remain relatively healthy into later
stages of life, eventually developing relatively mild,
organ-specific autoimmune symptoms depending on
their genetic background [20, 21]. Consistent with the







































Fig. 2 History of PD-1 research. Abbreviations: FIM, first in man; approved, FDA-approved; NCT, “National Clinical Trial” registry number in Clinical-
Trials.gov in the United States; FIM Pembrolizumab (P07990/MK-3475-001/KEYNOTE-001), NCT01295827; FIM Pidilizumab (CT-011), NCT00532259;
FIM BMS-936559 (MDX-1105), NCT00729664; FIM Atezolizumab, NCT01693562; FIM Durvalumab (MEDI4736), NCT01693562; FIM
Avelumab, NCT01772004
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mice, PD-1 inhibitors are less toxic than CTLA-4 in-
hibitors [34, 35].
Identification of PD-1 ligands
PD-L1 and PD-L2 were identified as PD-1 ligands in
2000 and 2001, respectively (Fig. 2) [9, 10]. PD-L1 and
PD-L2 are type I transmembrane proteins with IgV- and
IgC-like domains in the extracellular region. PD-L1 is
broadly expressed in both lymphoid and non-lymphoid
tissues. PD-L1 is upregulated upon activation on
hematopoietic cells, especially on antigen-presenting
cells (APCs) such as dendritic cells, macrophages/mono-
cytes, and B cells [36, 37]. PD-L1 is also expressed on
activated T cells. Importantly, PD-L1 is expressed on
non-lymphoid cells, including parenchymal cells and
vascular endothelial cells in the peripheral tissues, and is
upregulated by IFN-γ and other inflammatory cytokines
secreted by activated T cells [23, 26, 38]. The expression
of PD-L1 in peripheral tissues rather than on profes-
sional APCs is crucial for preventing autoimmune dam-
age to tissues [39]. Interestingly, PD-L1 is expressed in
various tumor cells and virus-infected cells. The expres-
sion of PD-L1 on target cells allows PD-1 to directly in-
hibit T-cell effector functions against the target cell.
Unlike PD-L1, which is expressed in many different tis-
sues, PD-L2 is expressed only on APCs such as dendritic
cells and macrophages [37].
Regulation of tumor immunity by PD-1
The PD-1/PD-L1 signaling pathway is crucial in damp-
ening immunosurveillance for tumors. Tumors can es-
cape host immune surveillance by expressing PD-L1,
which negatively regulates immune responses by inter-
acting with PD-1 on T cells (Fig. 1) [40]. Indeed, data
from clinical samples indicate that the high expression
of PD-1 ligands on tumors is correlated with a poor
prognosis [41, 42].
The first evidence of the PD-1/PD-L1 pathway’s in-
volvement in tumor immunity was found in animal
models [40]. PD-L1 overexpression on P815 mastocyto-
mas was shown to inhibit the cytolytic activity of CD8+
T cells by engaging PD-1 in vitro, and to markedly en-
hance tumorigenesis and tumor invasiveness in vivo.
Anti–PD-L1 treatment inhibited the growth of PD-L1–
expressing P815 tumor cells, and of J558L myeloma
cells, which endogenously express PD-L1. Importantly,
no tumors developed in Pdcd1−/− mice after their inocu-
lation with J558L cells. These results revealed the effect-
iveness of the PD-1/PD-L1 blockade for tumor therapy.
Although a CTLA-4 blockade enhances immune re-
sponses against immunogenic tumors such as lymphoma
in animal models, it is not effective as a single agent
against poorly immunogenic tumors such as B16 melan-
oma [43–45]. However, even as a single agent, a PD-1
blockade was found to be therapeutic against B16 mel-
anoma in a liver metastasis model [46]. These results
suggested that PD-1 blockade can be successfully applied
to metastatic tumors, and that it has a stronger thera-
peutic potential than does CTLA-4 blockade.
Clinical application of the PD-1/PD-L1 blockade
Several clinical studies have reported that PD-L1 overex-
pression is related to a poor prognosis for several types
of tumors, including renal-cell carcinoma, bladder can-
cer, esophageal cancer, pancreatic cancer, gastric cancer,
hepatocellular carcinoma, and ovarian cancer [41, 47–
53]. In ovarian cancer, PD-L1 expression is negatively
correlated with the number of intra-epithelial infiltrating
CD8+ T cells, suggesting that the PD-L1 expression on
tumor cells prevents CD8+ T cells from infiltrating
tumor sites [50]. These studies indicated that blocking
PD-1 signaling might improve clinical outcomes for pa-
tients with these malignancies. In 2006, a proof-of-
concept clinical study using a PD-1 signal inhibitor
against treatment-resistant solid tumors was initiated in
the United States (Fig. 2) [54].
A fully humanized monoclonal antibody (mAb) against
PD-1 (nivolumab; also known as ONO4538, MDX-1106,
or BMS-936558) was first developed using genetically
modified mice carrying loci encoding human immuno-
globulins. The IgG4 isotype of nivolumab minimizes
complement activity or antibody-dependent cell-
mediated cytotoxicity (ADCC) [54]. This antibody car-
ries a serine-to-proline substitution at position 228 to
minimize the effect of ADCC against activated T cells.
Clinical trials of nivolumab began in 2006 in the United
States and in 2009 in Japan (Fig. 2). The phase 1 study
of nivolumab showed cumulative response rates of 18%
for NSCLC, 28% for melanoma, and 27% for renal car-
cinoma. Grade 3 or 4 drug-related adverse events oc-
curred in 14% of the patients [35]. Notably, nivolumab
has demonstrated durable clinical activity as a single
agent, with far fewer side effects than are seen with ipili-
mumab, a mAb against CTLA-4 [34, 35]. A clinical trial
using anti–PDL1 mAbs (BMS-936559 or MDX-1105)
showed relatively low response rates compared to an
anti–PD-1 mAb [55].
The PD-1 blockade approach has unique features
compared to standard therapies. Conventional chemo-
therapies usually target a particular molecule in the
tumor cells. The tumor cells can escape the therapy with
mutations of the target molecules, leading to rapid re-
gression. However, a PD-1 blockade is applicable to a
wide range of cancers and provides a response over a
longer period because it activates an anti-tumor immune
system that can target mutated proteins [56]. In
addition, PD-1 blockade has a significantly lower rate of
high-grade toxicities than other immunotherapies or
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standard therapies, because the anti-tumor immunity
preferentially recognizes tumor-derived antigens, not
self-antigens. In a phase 3 study comparing nivolumab
to the plant alkaloid chemotherapy drug docetaxel in
272 patients with advanced squamous-cell NSCLC, the
response rate was 20% with nivolumab versus 9% with
docetaxel [57]. The overall survival rate at 1 year was
42% with nivolumab versus 24% with docetaxel. The fre-
quency of grade 3 or 4 treatment-related adverse events
was much lower in the nivolumab group (7%) than in
the docetaxel group (55%).
To date, at least 500 clinical studies with PD-1 signal
inhibitors have been conducted with nine types of anti-
bodies from eight pharmaceutical companies (Table 1
and Fig. 2) on at least 20 types of solid and
hematological malignant tumors (Table 2) [58]. The total
number of subjects worldwide is more than 20,000, ac-
cording to a clinical trials database managed by the U.S.
National Institutes of Health (https://clinicaltrials.gov/
[CTG]). The U.S. Food and Drug Administration (FDA)
approved nivolumab for patients with unresectable or
metastatic melanoma in 2014, for NSCLC in 2015, and
for classical Hodgkin’s lymphoma and RCC in 2016. The
FDA also approved pembrolizumab for melanoma in
2014 and for NSCLC in 2015. Atezolizumab, an anti–
PD-L1 antibody, was approved for unresectable bladder
cancer and for NSCLC in 2016.
Regarding clinical trials for ovarian cancer, we first
conducted the principal investigator-initiated two-cohort
(1 or 3 mg/kg, n = 10 each) phase 2 clinical trial of nivo-
lumab in 20 patients with platinum-resistant recurrent
ovarian cancer at Kyoto University Hospital in 2011
(Fig. 2) (UMIN000005714) [59, 60]. The objective re-
sponse rate at 3 mg/kg was 20%; this included two cases
of complete response (CR). For all 20 patients, the re-
sponse rate was 15% and the durable CR (DCR) was
45%. The median progression-free survival (PFS) and
overall survival (OS) were 3.5 and 20.0 months, respect-
ively [60]. In our ongoing follow-up study of this trial, a
durable anti-tumor response with nivolumab has been
observed in two patients with a complete response for
over 1 year. After completing the 1-year nivolumab
treatment, these two patients survived without any anti-
tumor treatment for over 2 years [61, 62]. Based on this
positive result, we are conducting a large randomized
phase 2 trial with nivolumab versus standard 2nd-line
chemotherapy (NINJA study, JapicCTI-153004). So far,
at least 30 clinical trials have been completed or are un-
derway for ovarian cancers using the monotherapeutic
anti–PD-1 antibody pembrolizumab (response rate [RR]
10%, n = 104) [63], the anti–PD-L1 antibody avelumab
(RR 10%, n = 104) [64], or combinations of these agents
with conventional cancer therapies (CTG).
Combination therapy with blockade of PD-1/PD-
L1 signal and new co-signals
Patients who respond poorly or are unresponsive to im-
munotherapies appear to lack preexisting anti-tumor T-
Table 1 PD-1 signal inhibitors (anti–PD-1 and anti–PD-L1 antibodies) in clinical trials
Target Agent IgG class Company Approved
PD-1 nivolumab (Opdivo®, BMS-936558, MDX1106) Human IgG4 Bristol-Meyers Squibb/Ono MelanomaU, E, J
Lung cancerU, E, J
Kidney cancerU, J
Hodgkin’s lymphoma U, E,
J




Humanized IgG4 Merck MelanomaU, E, J
Lung cancerU, E, J
Head and neck cancerU
pidilizumab (CT-011) Humanized IgG1k Cure Tech




AMP-514 (MEDI0680) PD-L2 fusion protein Amplimmune/GlaxoSmith
Klein
PDR001 Humanized IgG4 Novartis Pharmaceuticals
PD-L1 BMS-936559 (MDX1105) Human IgG4 Bristol-Meyers Squibb
atezolizumab (Tecentriq®, MPDL3280A) Humanized IgG1k Roche/Genentech Urothelial cancerU
Lung cancerU
durvalumab (MEDI4736) Human IgG1k MedImmune/AstraZeneca
avelumab (MSB0010718C) Human IgG1 Merck Serono/Pfizer
All antibodies used in clinical trials as of September 1, 2016 were extracted from ClinicalTrials.gov
Abbreviations: U U.S. Food and Drug Administration (FDA) approved; E European Medicines Agency (EMA) approved, J Japanese Pharmaceutical and Medical
Devices Agency (PMDA) approved
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Table 2 Clinical effects of monotherapeutic PD-1 signal inhibitors on several types of malignancies
Target Agent Phase Clinical effect Reference
melanoma pembrolizumab 2 6MOS 34% (2 mg/kg) vs. 38% (10 mg/kg), vs 16% :docetaxel (n = 540) [88]
3 1 year-OS 74% (2wks) vs. 38% (3wks), vs 11% :docetaxel (n = 834) [89]
nivolumab 3 1 year-OS 73% vs 42% (dacarbazine) (n = 418) [89]
3 ORR 32% vs. 11% (dacarbazine) (n = 405) [90]
non-small cell lung cancer pembrolizumab 1 ORR 19.4%, mOS12.5 M (total), ORR 45.2% (n = 72, PD-L1+) (n = 495) [91]
nivolumab 3 mOS 9.2 M (vs 6.0 M:docetaxel) (n = 272) [57]
3 mOS12.2 M (vs 9.7 M:docetaxel (n = 582) [92]
durvalumab 1/2 ORR 14% (n = 149, total), 23% (PD-L1+) [72]
atezolizumab 2 ORR 15% (n = 144, total), 38% (n = 24, PD-L1+) [93]
small cell lung cancer nivolumab 1/2 ORR 18% (n = 40, nivo), 17% (n = 46, combined with chemotherapy) [94]
pembrolizumab 1 ORR 25% (n = 16) [95]
head and neck cancer durvalumab 1/2 ORR 12% (n = 62) [96]
pembrolizumab 1 ORR 24.8% (n = 117) [97]
renal cell cancer nivolumab 3 ORR 25%, mOS 25.0 M, (vs. ORR 5%, mOS 19Ms in everolimus)
(n = 821)
[98]
bladder cancer atezolizumab 1 ORR 26% (n = 310, total), 43% (PD-L1+) [99]
pembrolizumab 1 ORR 25% (n = 33, total), 38% (PD-L1+) [100]
ovarian cancer nivolumab 2 ORR 15% (n = 20, total), mOS 20.0 M ORR 20% (n = 10, 3 mg/kg) [60]
avelumab 1 ORR 10% (n = 124) [101]
pembrolizumab 1 ORR 11.5% (PD-L1+) (n = 49) [63]
uterine endometrial cancer pembrolizumab 1 ORR 12.5% (PD-L1+) (n = 24) [102]
uterine cervical cancer pembrolizumab 1 ORR 12.5% (PD-L1+) (n = 24) [103]
uterine sarcoma nivolumab 1 ORR 0% (n = 12) [104]
gastric cancer pembrolizumab 1 ORR 31% (n = 39) [79]
esophageal cancer pembrolizumab 1 ORR 30% (PD-L1+) (n = 23) [105]
DNA mismatch repair deficient colon pembrolizumab 2 ORR 40% (n = 10, MMRd colon), vs 0% (n = 18) in MMRw, vs71% (n = 7),
MMR-non-colon [cholangiocarcinoma, endometrial cancer and
pancreatic cancer].)
[73].
DNA mismatch repair deficient
endometrial cancer
pembrolizumab 2 ir-ORR 67% (n = 9) [106]
hepatocellular carcinoma nivolumab 1/2 ORR 9% (n = 91), 6 month-OS 69%. [107]
breast cancer atezolizumab 1 ORR 12% (n = 27) [108]
pembrolizumab 1 ORR 19% (n = 25) (PD-L1+) [109]
Merkel cell carcinoma pembrolizumab 2 ORR 56% (n = 25), 6 M-PFS 67% [110]
thyroid cancer pembrolizumab 1 ORR 9.1% (n = 22), mOS not reached, 1 year-OS 89.9%. [111]
Hodgikin lymphoma nivolumab 1 ORR 87%, 24wks-PFS 86%(n = 23) [112]
pembrolizumab 1 ORR 64% (n = 31), 52wks-PFS 46%. [113]
follicular lymphoma nivolumab 1 ORR 40% (n = 10) [114]
diffuse large B-cell lymphoma nivolumab 1 ORR 36% (n = 11) [114]
mycosisfungoides nivolumab 1 ORR 15% (n = 13) [114]
peripheral T-cell lymphoma nivolumab 1 ORR 40% (n = 5) [114]
Partially modified from reference [58]. Abbreviations: M month, wk week, ORR objective response rate, OS overall survival, PFS progression-free survival, irRC
immune-related response criteria, ASCO Annual meeting of the American Society of Clinical Oncology, SGO Annual meeting of the Society of Gynecologic Oncol-
ogy, Abst Abstract, MMRd DNA mismatch repair deficient, MMRw DNA mismatch repair wild
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cell responses. One possible approach to overcoming this
issue is to combine the two immune-checkpoint inhibitors
anti–PD-1 and anti–CTLA-4 (Fig. 1). In a phase 1 study
on patients with advanced melanoma, concurrent therapy
with nivolumab and ipilimumab induced rapid and dur-
able responses, resulting in an unprecedented 2-year sur-
vival rate of over 80%; 53% of the patients had an
objective response with more than 80% tumor reduction
[65]. However, grade 3 or 4 therapy-related adverse events
occurred in 53% of the patients. In this double-blind
study, 142 patients with metastatic melanoma ran-
domly received ipilimumab combined with nivolumab
or placebo once every 3 weeks for four doses. The
objective response rate was significantly higher for pa-
tients who received the combined ipilimumab and
nivolumab regimen (60%) compared to those treated
with ipilimumab monotherapy (11%). The median PFS
was 8.9 months with the combination therapy and
4.7 months with ipilimumab alone [66]. Based on this
confirmatory trial, the FDA approved this combined
nivolumab and ipilimumab therapy for unresectable
or metastatic melanoma in 2015. Combined nivolu-
mab and ipilimumab therapy is now being clinically
applied to other cancer types, including RCC [67],
NSCLC [68], and ovarian cancer (NCT02498600).
However, the frequency of grade 3 or 4 immune-
related adverse events (irAEs) is over 50%, and this
issue remains to be resolved [69].
Several clinical trials are underway for PD-1 inhibitors
in combination with other immune-checkpoint inhibi-
tors, immune activators, and chemotherapies (Table 3
and Fig. 1). However, combining immunotherapies with
chemotherapies can increase irAEs. For example, com-
pared to PD-L1 mAb (durvalumab) or EGFR inhibitor
(osimertinib) monotherapies, combining the two therap-
ies induced a significantly higher risk of interstitial lung
disease (2% [n = 23 of 1149], 2.8% [35 of 1207], and 38%
[n = 13 of 34], respectively) [70]. At present, at least 20
clinical trials with combined PD-1 inhibitors and focal
radiation therapy and more than five trials combining
anti-PD-1 mAb with chemoradiation therapy are under-
way (CTG).
Biomarkers for predicting the efficacy of the PD-
1-blockade cancer immunotherapy
Potential predictive biomarkers for anti-tumor responses
with PD-1 inhibitors can be found among both tumor
cell-related factors and host immunological factors. Re-
cent reports identified the frequency of genetic muta-
tions derived from microsatellite instability (MSI) with
DNA mismatch repair deficiency (MMRd) in cancer
cells as a candidate biomarker [56, 71–73]. Many mu-
tated neo-antigens expressed on the surface of cancer
cells are recognized by T cells and B cells as foreign
antigens, either directly or through the APC system.
Cancer cells exposed to IFN-γ released from activated T
cells express PD-L1, thereby establishing an acquired
immune resistance [74]; in this case, PD-1 signal inhibi-
tors are more likely to be effective. Thus, genome-wide
mutation analysis (i.e., Mutanome) of cancer cells using
next-generation sequencing technology and diversity
analysis of the T-cell or B-cell repertoire (i.e., Immu-
nome) have attracted a lot of attention as strategies for
identifying predictive biomarkers (Fig. 3) [75, 76]. Based
on this concept, researchers have examined candidate
biomarkers such as the PD-L1 level on tumor cells and
the frequency of tumor-infiltrating lymphocytes [77, 78],
the levels of IFN-γ–related genes in tumor cells [79, 80],
the frequency of mutations in tumor cells [56, 71–73],
and the diversity of TCRs in tumor antigen–specific T
cells [74, 81, 82]. However, these candidates do not al-
ways correspond to a high response according to cancer
type. For example, clinical trials of PD-1 inhibitors for
squamous-cell lung cancer and ovarian cancer showed
no correlation between clinical effect and PD-L1 expres-
sion on tumor tissues [57, 60, 64]. A recent report by
Hugo et al. revealed that high mutational loads and
genes related to T-cell checkpoints, such as CD8A/B,
PD-L1, LAG3, and IFN-γ, in tumor tissues were not as-
sociated with responsiveness in breast cancer patients
[83]. Interestingly, the breast cancer susceptibility gene
(BRCA) 2 mutation status is associated with responsive-
ness to PD-1 mAb therapy [83], while no correlation
was found between BRCA2 and avelumab’s clinical effect
on ovarian cancer [64]. It is urgent to validate current
candidates and to discover new biomarkers for clinical
response to PD-1 signal inhibitors.
Toxicities of PD-1/PD-L1 signal blocking
IrAEs associated with PD-1 blockade therapy include
interstitial pneumonitis, colitis with gastrointestinal per-
foration, type 1 diabetes, severe skin reactions, immune
thrombocytopenia, neutropenia and sepsis after cortico-
steroid therapy, encephalopathy and neurological seque-
lae, Guillain-Barré syndrome, myelitis, myasthenia
gravis, myocarditis and cardiac insufficiency, acute ad-
renal insufficiency, and nephritis [84–87]. Based on sev-
eral previous clinical trials, guidelines and specific care
algorithms have been established for the identification,
early intervention, and management of irAEs [86, 87].
While irAEs can develop at any time, most of the im-
mune toxicities of nivolumab occur within the first
4 months [86, 87]. The median time to onset of irAEs
tends to differ depending on the type of toxicity, and
can be roughly classified as early (<2 months: skin,
gastrointestinal, or hepatic irAEs) or late (>2 months:
pulmonary, endocrine, and renal-related irAEs). To treat
new types of adverse events and to reduce the frequency
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of immunological toxicities, oncologists should form and
collaborate with networks of organ-specific medical doc-
tors, pharmacists, and nurses.
Conclusion
Basic and translational studies in the 20 years since PD-
1’s discovery have demonstrated the concept of immune
surveillance in mice and humans. The recovery of T-cell
anergy by blocking PD-1 signals on T cells yielded in-
credible clinical benefits for several types of malignan-
cies. Nevertheless, there is a still a great deal of
exploratory research needed to clarify the fundamental
mechanism and predictive biomarkers for the efficacy
and adverse effects of this therapeutic strategy. To
advance the development of PD-1 signal inhibitors in
cancer therapy, it is important to continue both
Table 3 Clinical trials of combination therapies with molecularly targeted drugs
PD-1/PD-L1mAb Combination Tumor Reference
PD-1 mAb (Nivolumab) LAG3 (BMS-986016) Solid Tumors NCT01968109
PD-1 mAb (Nivolumab) B7-H3 (Enoblituzumab) Solid Tumors NCT02817633
PD-1 mAb (Pembrolizumab) B7-H3 (Enoblituzumab) Solid Tumors NCT02475213
PD-1 mAb (Nivolumab) KIR (Lirilumab) Solid Tumors NCT01714739
PD-L1 mAb (MEDI4736) OX40 (MEDI6383) Solid Tumors NCT02221960
PD-1 mAb (Nivolumab) 4-1BB (Urelumab) Solid tumors and B-cell non-Hodgkin lymphoma NCT02253992
PD-1 mAb (Nivolumab) ICOS (JTX-2011) Solid Tumors NCT02904226
Pd-1 mAb (PDR001) GITR (GWN323) Solid Tumors and Lymphomas NCT02740270
PD-1 mAb (Nivolumab) CD27 (Varlilumab) Solid Tumors NCT02335918
PD-L1 mAb (Atezolizumab) CD27 (Varlilumab) Solid Tumors NCT02543645
PD-1 mAb (Nivolumab) GM.CD40L (vaccine for NSCLC) Lung (NSCLC) NCT02466568
PD-L1 mAb (Atezolizumab) VEGF inhibitors (Bevacizumab cediranib) Ovarian Cancer NCT02659384
PD-L1 mAb (MEDI4736) PARP inhibitors (Olaparib) S tumors NCT02484404
PD-L1 mAb (MEDI4736) Multi-kinase inhibitor (Sunitinib) Solid tumors NCT02484404
PD-1 mAb (Pembrolizumab) with SBRT Multi-kinase inhibitor (Sunitinib) TKI refractory mRCCa NCT02599779
PD-L1 mAb (Durvalumab) EGFR inhibitor (Osimertinib) Lung (NSCLC) reference [70]
a Tyrosine kinase inhibitor refractory metastatic recal cell cancer
2. Neo-antigen 4. T cell/B cell 
activation and expansion
1. Genetic mutation
3. Recognizing and presenting neo-epitopeMutanome
Immunome
PD-L1/PD-1 signal induces acquired immunosuppression   
PD-1 signal inhibitors may be effective ?
5. IFN- releasing
6. Upregulation of PD-L1
Fig. 3 Genomic mutations and PD-1 signal inhibitors. (1) Genetic mutations in cancer cells create neo-antigens. (2) Neo-antigens are expressed on the
surface of the cancer cells. (3) Recognition of a neo-antigen as a foreign body by an APC induces a T-cell response, and (4) consequently activates
T cells and B cells. (5) Activated T cells release IFN-γ. (6) A cancer cell that is exposed to IFN-γ expresses PD-L1, thereby establishing an acquired
immune resistance. In this particular tumor microenvironment, PD-1 signal inhibitors appear to be effective; thus, genome-wide mutation analysis
(i.e., Mutanome) of cancer cells using next-generation sequencing technology and diversity analysis of the T-cell or B-cell repertoire (i.e., Immu-
nome) are valuable next strategies for identifying predictive biomarkers [75]. APC, antigen-presenting cell
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translational and reverse-translational research ap-
proaches, including molecular and genomic studies to
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